Therefore, close monitoring of Hb, Hct, and erythrocytes levels, as well as any symptoms associated with erythrocytosis may be suggested in patients treated with regorafenib and exploring the potential association between the occurrence of erythrocytosis and the clinical outcome might be warranted. The gene discussed is GSTM1; the disease is polycythemia.